ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Grifols SA Develops plasma-derived medicines and transfusion solutions for rare and chronic conditions.	United States of America	GRFS
Grindeks Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.	Latvia	GRD1R
GSK plc Develops specialty medicines and vaccines to prevent and treat a range of global diseases.	United States of America	GSK
GT Biopharma, Inc. Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.	United States of America	GTBP
Guardant Health, Inc. Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.	United States of America	GH
Guard Therapeutics International AB Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.	Sweden	GUARD
GW Vitek CO.,LTD. Develops research antibodies and distributes scientific instruments for life science researchers.	South Korea	036180
GYRE THERAPEUTICS, INC. Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.	United States of America	GYRE
Haleon plc A consumer healthcare leader offering trusted OTC brands for everyday health and wellness.	United States of America	HLN
Haleon PLC A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.	United Kingdom	HLN